Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Inactivation of mTORC2 in macrophages is a signature of colorectal cancer that promotes tumorigenesis.

Katholnig K, Schütz B, Fritsch SD, Schörghofer D, Linke M, Sukhbaatar N, Matschinger JM, Unterleuthner D, Hirtl M, Lang M, Herac M, Spittler A, Bergthaler A, Schabbauer G, Bergmann M, Dolznig H, Hengstschläger M, Magnuson MA, Mikula M, Weichhart T.

JCI Insight. 2019 Oct 17;4(20). pii: 124164. doi: 10.1172/jci.insight.124164.

2.

Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis.

Calender A, Lim CX, Weichhart T, Buisson A, Besnard V, Rollat-Farnier PA, Bardel C, Roy P, Cottin V, Devouassoux G, Finat A, Pinson S, Lebecque S, Nunes H, Israel-Biet D, Bentaher A, Valeyre D, Pacheco Y; in the frame of GSF (Group Sarcoidosis France).

Eur Respir J. 2019 Aug 1;54(2). pii: 1900430. doi: 10.1183/13993003.00430-2019. Print 2019 Aug. No abstract available.

PMID:
31023854
3.

Iron Regulation: Macrophages in Control.

Sukhbaatar N, Weichhart T.

Pharmaceuticals (Basel). 2018 Dec 14;11(4). pii: E137. doi: 10.3390/ph11040137. Review.

4.

TORching a semaphore for alternative macrophage activation.

Wilson JL, Weichhart T.

Nat Immunol. 2018 Jun;19(6):512-514. doi: 10.1038/s41590-018-0117-z. No abstract available.

PMID:
29777214
5.

mTOR Senses Environmental Cues to Shape the Fibroblast-like Synoviocyte Response to Inflammation.

Karonitsch T, Kandasamy RK, Kartnig F, Herdy B, Dalwigk K, Niederreiter B, Holinka J, Sevelda F, Windhager R, Bilban M, Weichhart T, Säemann M, Pap T, Steiner G, Smolen JS, Kiener HP, Superti-Furga G.

Cell Rep. 2018 May 15;23(7):2157-2167. doi: 10.1016/j.celrep.2018.04.044.

6.

Whole exome sequencing in three families segregating a pediatric case of sarcoidosis.

Calender A, Rollat Farnier PA, Buisson A, Pinson S, Bentaher A, Lebecque S, Corvol H, Abou Taam R, Houdouin V, Bardel C, Roy P, Devouassoux G, Cottin V, Seve P, Bernaudin JF, Lim CX, Weichhart T, Valeyre D, Pacheco Y, Clement A, Nathan N; in the frame of GSF (Groupe Sarcoïdose France).

BMC Med Genomics. 2018 Mar 6;11(1):23. doi: 10.1186/s12920-018-0338-x.

7.

mTOR as Regulator of Lifespan, Aging, and Cellular Senescence: A Mini-Review.

Weichhart T.

Gerontology. 2018;64(2):127-134. doi: 10.1159/000484629. Epub 2017 Dec 1. Review.

8.

Pro- versus Anti-inflammatory Actions of HDLs in Innate Immunity.

Kopecky C, Michlits G, Säemann MD, Weichhart T.

Cell Metab. 2017 Jul 5;26(1):2-3. doi: 10.1016/j.cmet.2017.04.007. Epub 2017 Jun 22.

9.

mTORC1 and mTORC2 as regulators of cell metabolism in immunity.

Linke M, Fritsch SD, Sukhbaatar N, Hengstschläger M, Weichhart T.

FEBS Lett. 2017 Oct;591(19):3089-3103. doi: 10.1002/1873-3468.12711. Epub 2017 Jun 23. Review.

10.

A New Immunomodulatory Role for Peroxisomes in Macrophages Activated by the TLR4 Ligand Lipopolysaccharide.

Vijayan V, Srinu T, Karnati S, Garikapati V, Linke M, Kamalyan L, Mali SR, Sudan K, Kollas A, Schmid T, Schulz S, Spengler B, Weichhart T, Immenschuh S, Baumgart-Vogt E.

J Immunol. 2017 Mar 15;198(6):2414-2425. doi: 10.4049/jimmunol.1601596. Epub 2017 Feb 8.

11.

Chronic signaling via the metabolic checkpoint kinase mTORC1 induces macrophage granuloma formation and marks sarcoidosis progression.

Linke M, Pham HT, Katholnig K, Schnöller T, Miller A, Demel F, Schütz B, Rosner M, Kovacic B, Sukhbaatar N, Niederreiter B, Blüml S, Kuess P, Sexl V, Müller M, Mikula M, Weckwerth W, Haschemi A, Susani M, Hengstschläger M, Gambello MJ, Weichhart T.

Nat Immunol. 2017 Mar;18(3):293-302. doi: 10.1038/ni.3655. Epub 2017 Jan 16.

12.

Effects of Interferons and Viruses on Metabolism.

Fritsch SD, Weichhart T.

Front Immunol. 2016 Dec 21;7:630. doi: 10.3389/fimmu.2016.00630. eCollection 2016. Review.

13.

mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function.

Sukhbaatar N, Hengstschläger M, Weichhart T.

Trends Immunol. 2016 Nov;37(11):778-789. doi: 10.1016/j.it.2016.08.009. Epub 2016 Sep 7. Review.

14.

HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.

Kopecky C, Ebtehaj S, Genser B, Drechsler C, Krane V, Antlanger M, Kovarik JJ, Kaltenecker CC, Parvizi M, Wanner C, Weichhart T, Säemann MD, Tietge UJ.

J Am Soc Nephrol. 2017 Mar;28(3):769-775. doi: 10.1681/ASN.2016030262. Epub 2016 Sep 9.

15.

Applied immuno-epidemiological research: an approach for integrating existing knowledge into the statistical analysis of multiple immune markers.

Genser B, Fischer JE, Figueiredo CA, Alcântara-Neves N, Barreto ML, Cooper PJ, Amorim LD, Saemann MD, Weichhart T, Rodrigues LC.

BMC Immunol. 2016 May 20;17(1):11. doi: 10.1186/s12865-016-0149-9.

16.

Regulation of innate immune cell function by mTOR.

Weichhart T, Hengstschläger M, Linke M.

Nat Rev Immunol. 2015 Oct;15(10):599-614. doi: 10.1038/nri3901. Review.

17.

Effects of the mTOR inhibitor everolimus and the PI3K/mTOR inhibitor NVP-BEZ235 in murine acute lung injury models.

Üstün S, Lassnig C, Preitschopf A, Mikula M, Müller M, Hengstschläger M, Weichhart T.

Transpl Immunol. 2015 Sep;33(1):45-50. doi: 10.1016/j.trim.2015.06.001. Epub 2015 Jun 11.

18.

HDL cholesterol efflux capacity and cardiovascular events.

Kopecky C, Weichhart T, Säemann MD.

N Engl J Med. 2015 May 7;372(19):1869. doi: 10.1056/NEJMc1503139. No abstract available.

PMID:
25946299
19.

Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.

Kopecky C, Genser B, Drechsler C, Krane V, Kaltenecker CC, Hengstschläger M, März W, Wanner C, Säemann MD, Weichhart T.

Clin J Am Soc Nephrol. 2015 Feb 6;10(2):224-31. doi: 10.2215/CJN.06560714. Epub 2014 Nov 25.

20.

Lysis gradient centrifugation: a flexible method for the isolation of nuclei from primary cells.

Katholnig K, Poglitsch M, Hengstschläger M, Weichhart T.

Methods Mol Biol. 2015;1228:15-23. doi: 10.1007/978-1-4939-1680-1_2.

PMID:
25311118
21.

mTORC1 is essential for early steps during Schwann cell differentiation of amniotic fluid stem cells and regulates lipogenic gene expression.

Preitschopf A, Li K, Schörghofer D, Kinslechner K, Schütz B, Thi Thanh Pham H, Rosner M, Joo GJ, Röhrl C, Weichhart T, Stangl H, Lubec G, Hengstschläger M, Mikula M.

PLoS One. 2014 Sep 15;9(9):e107004. doi: 10.1371/journal.pone.0107004. eCollection 2014.

22.

Restoration of renal function does not correct impairment of uremic HDL properties.

Kopecky C, Haidinger M, Birner-Grünberger R, Darnhofer B, Kaltenecker CC, Marsche G, Holzer M, Weichhart T, Antlanger M, Kovarik JJ, Werzowa J, Hecking M, Säemann MD.

J Am Soc Nephrol. 2015 Mar;26(3):565-75. doi: 10.1681/ASN.2013111219. Epub 2014 Jul 28.

23.

Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production.

Fruhwürth S, Krieger S, Winter K, Rosner M, Mikula M, Weichhart T, Bittman R, Hengstschläger M, Stangl H.

Biochim Biophys Acta. 2014 Jul;1841(7):944-53. doi: 10.1016/j.bbalip.2014.03.014. Epub 2014 Apr 5.

24.

Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.

Duran I, Goebell PJ, Papazisis K, Ravaud A, Weichhart T, Rodriguez-Portal JA, Budde K.

Expert Opin Drug Saf. 2014 Mar;13(3):361-72. doi: 10.1517/14740338.2014.888056. Epub 2014 Feb 11. Review.

PMID:
24517115
25.

Immune responses of macrophages and dendritic cells regulated by mTOR signalling.

Katholnig K, Linke M, Pham H, Hengstschläger M, Weichhart T.

Biochem Soc Trans. 2013 Aug;41(4):927-33. doi: 10.1042/BST20130032. Review.

26.

Hereditary amyloidosis caused by R554L fibrinogen Aα-chain mutation in a Spanish family and review of the literature.

Haidinger M, Werzowa J, Kain R, Antlanger M, Hecking M, Pfaffenberger S, Mascherbauer J, Gremmel T, Gilbertson JA, Rowczenio D, Weichhart T, Kopecky C, Hörl WH, Hawkins PN, Säemann MD.

Amyloid. 2013 Jun;20(2):72-9. doi: 10.3109/13506129.2013.781998. Epub 2013 Apr 3.

PMID:
23551149
27.

p38α senses environmental stress to control innate immune responses via mechanistic target of rapamycin.

Katholnig K, Kaltenecker CC, Hayakawa H, Rosner M, Lassnig C, Zlabinger GJ, Gaestel M, Müller M, Hengstschläger M, Hörl WH, Park JM, Säemann MD, Weichhart T.

J Immunol. 2013 Feb 15;190(4):1519-27. doi: 10.4049/jimmunol.1202683. Epub 2013 Jan 11.

28.

PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga PP, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger JM, Jaeger U, Moriggl R, Inghirami G, Kenner L.

Nat Med. 2012 Nov;18(11):1699-704. doi: 10.1038/nm.2966. Epub 2012 Oct 14.

29.

Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial.

Hecking M, Antlanger M, Winnicki W, Reiter T, Werzowa J, Haidinger M, Weichhart T, Polaschegg HD, Josten P, Exner I, Lorenz-Turnheim K, Eigner M, Paul G, Klauser-Braun R, Hörl WH, Sunder-Plassmann G, Säemann MD.

Trials. 2012 Jun 8;13:79. doi: 10.1186/1745-6215-13-79.

30.

CMV late phase-induced mTOR activation is essential for efficient virus replication in polarized human macrophages.

Poglitsch M, Weichhart T, Hecking M, Werzowa J, Katholnig K, Antlanger M, Krmpotic A, Jonjic S, Hörl WH, Zlabinger GJ, Puchhammer E, Säemann MD.

Am J Transplant. 2012 Jun;12(6):1458-68. doi: 10.1111/j.1600-6143.2012.04002.x. Epub 2012 Mar 5.

31.

Serum amyloid A in uremic HDL promotes inflammation.

Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, Suarna C, Eller P, Tölle M, Gerner C, Zlabinger GJ, van der Giet M, Hörl WH, Stocker R, Säemann MD.

J Am Soc Nephrol. 2012 May;23(5):934-47. doi: 10.1681/ASN.2011070668. Epub 2012 Jan 26.

32.

Apoptotic cell-free DNA promotes inflammation in haemodialysis patients.

Atamaniuk J, Kopecky C, Skoupy S, Säemann MD, Weichhart T.

Nephrol Dial Transplant. 2012 Mar;27(3):902-5. doi: 10.1093/ndt/gfr695. Epub 2011 Dec 13.

PMID:
22167588
33.

Mammalian target of rapamycin: a signaling kinase for every aspect of cellular life.

Weichhart T.

Methods Mol Biol. 2012;821:1-14. doi: 10.1007/978-1-61779-430-8_1. Review.

PMID:
22125056
34.

Rapid isolation of nuclei from living immune cells by a single centrifugation through a multifunctional lysis gradient.

Poglitsch M, Katholnig K, Säemann MD, Weichhart T.

J Immunol Methods. 2011 Oct 28;373(1-2):167-73. doi: 10.1016/j.jim.2011.08.012. Epub 2011 Aug 24.

PMID:
21889513
35.

Targeting the dysregulated mammalian target of rapamycin pathway in organ transplantation: killing 2 birds with 1 stone.

Haidinger M, Werzowa J, Weichhart T, Säemann MD.

Transplant Rev (Orlando). 2011 Oct;25(4):145-53. doi: 10.1016/j.trre.2010.11.001. Epub 2011 Mar 17. Review.

PMID:
21419611
36.

Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells.

Weichhart T, Haidinger M, Katholnig K, Kopecky C, Poglitsch M, Lassnig C, Rosner M, Zlabinger GJ, Hengstschläger M, Müller M, Hörl WH, Säemann MD.

Blood. 2011 Apr 21;117(16):4273-83. doi: 10.1182/blood-2010-09-310888. Epub 2011 Mar 2.

PMID:
21368289
37.

Sirolimus and kidney transplantation: unraveling an inflammatory affair.

Weichhart T, Säemann MD.

Am J Transplant. 2010 Dec;10(12):2569-70. doi: 10.1111/j.1600-6143.2010.03306.x. No abstract available.

38.

A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation.

Haidinger M, Werzowa J, Voigt HC, Pleiner J, Stemer G, Hecking M, Döller D, Hörl WH, Weichhart T, Säemann MD.

Trials. 2010 Oct 6;11:91. doi: 10.1186/1745-6215-11-91.

39.

A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation.

Haidinger M, Poglitsch M, Geyeregger R, Kasturi S, Zeyda M, Zlabinger GJ, Pulendran B, Hörl WH, Säemann MD, Weichhart T.

J Immunol. 2010 Oct 1;185(7):3919-31. doi: 10.4049/jimmunol.1000296. Epub 2010 Aug 30.

40.

The versatility of HDL: a crucial anti-inflammatory regulator.

Säemann MD, Poglitsch M, Kopecky C, Haidinger M, Hörl WH, Weichhart T.

Eur J Clin Invest. 2010 Dec;40(12):1131-43. doi: 10.1111/j.1365-2362.2010.02361.x. Review.

PMID:
20695882
41.

T helper cell differentiation: understanding the needs of hierarchy.

Weichhart T, Säemann MD.

Immunity. 2010 Jun 25;32(6):727-9. doi: 10.1016/j.immuni.2010.06.008.

42.

Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates.

Wahrmann M, Haidinger M, Körmöczi GF, Weichhart T, Säemann MD, Geyeregger R, Kikić Z, Prikoszovich T, Drach J, Böhmig GA.

Transplantation. 2010 Jun 15;89(11):1385-90. doi: 10.1097/TP.0b013e3181d9e1c0.

PMID:
20335829
43.

Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance.

Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, Säemann MD, Geyeregger R, Schlederer M, Kenner L, Stulnig TM.

Diabetes. 2010 Apr;59(4):935-46. doi: 10.2337/db09-0404. Epub 2010 Jan 27.

44.

Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.

Haidinger M, Hecking M, Weichhart T, Poglitsch M, Enkner W, Vonbank K, Prayer D, Geusau A, Oberbauer R, Zlabinger GJ, Soleiman A, Hörl WH, Säemann MD.

Transpl Int. 2010 Aug;23(8):777-85. doi: 10.1111/j.1432-2277.2009.01041.x. Epub 2010 Jan 11.

45.

The anti-inflammatory potency of dexamethasone is determined by the route of application in vivo.

Weichhart T, Brandt O, Lassnig C, Müller M, Hörl WH, Stingl G, Säemann MD.

Immunol Lett. 2010 Mar 10;129(1):50-2. doi: 10.1016/j.imlet.2009.12.025. Epub 2010 Jan 12.

PMID:
20060857
46.

The multifunctional role of mTOR in innate immunity: implications for transplant immunity.

Säemann MD, Haidinger M, Hecking M, Hörl WH, Weichhart T.

Am J Transplant. 2009 Dec;9(12):2655-61. doi: 10.1111/j.1600-6143.2009.02832.x. Epub 2009 Sep 25. Review.

47.

The multiple facets of mTOR in immunity.

Weichhart T, Säemann MD.

Trends Immunol. 2009 May;30(5):218-26. doi: 10.1016/j.it.2009.02.002. Epub 2009 Apr 8. Review.

PMID:
19362054
48.

Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept.

Haidinger M, Hecking M, Memarsadeghi M, Weichhart T, Werzowa J, Hörl WH, Säemann MD.

Transpl Infect Dis. 2009 Apr;11(2):171-4. doi: 10.1111/j.1399-3062.2009.00366.x. Epub 2009 Feb 5.

PMID:
19210692
49.

The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications.

Weichhart T, Säemann MD.

Ann Rheum Dis. 2008 Dec;67 Suppl 3:iii70-4. doi: 10.1136/ard.2008.098459. Review.

PMID:
19022819
50.

The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, Müller M, Säemann MD.

Immunity. 2008 Oct 17;29(4):565-77. doi: 10.1016/j.immuni.2008.08.012. Epub 2008 Oct 9.

Supplemental Content

Loading ...
Support Center